We report the effects exerted by cytokine combinations, including stem cell factor (SCF), interleukin-7, interleukin-4 and interleukin-2, on the amplification of T cells from cord blood (CB) mononuclear cells cultured for 10-11 days under serum-deprived conditions. Of all the combinations investigated, SCF+interleukin-7 sustained the best fold increase (FI) of total nucleated cells (FI ¼ 6.471.17), amplifying preferentially CD4 + over CD8 + T-cell subsets (FI ¼ 4.7270.79 vs 2.7371.2, respectively, Po0.05). The addition of interleukin-2 to this combination did not significantly increase the total number of cells generated (FI ¼ 7.472.27), but allowed preferential amplification of CD8 + over CD4 + T cells (FI ¼ 6.0470.14 vs 1.6770.6, respectively, Po0.05). Single-strand conformation polymorphism analysis of the T-cell receptor V b -chain rearrangements expressed by the expanded T cells indicated that the complexity of the T-cell repertoire had increased after 10 days of culture in the presence of SCF and IL-7. Interestingly, a modest expansion (FI ¼ 8.6771.5) of myeloid progenitor cells was also observed in these cultures. These results indicate that it is possible to expand specific T-cell subsets for adoptive immunotherapy without losing myeloid progenitor cells necessary for neutrophil recovery after CB transplantation, by modulating the cytokines added to the cultures.
interleukin-7; interleukin-2; serum-free cultures; ex vivo amplification The use of cord blood (CB) as an alternative source of hemopoietic stem cells for allo-transplantation of pediatric patients is steadily increasing. 1 These transplant recipients experience a rate of engraftment similar to that reported for allogeneic adult marrow transplants, but their follow-up is characterized by reduced incidence of graft-versus-host disease (GVHD). 2 The reduced GVHD has been explained by the low immune reactivity of neonatal circulating T lymphocytes [3] [4] [5] and may result in a reduced graft-versusleukemia (GVL) effect as well.
Donor lymphocyte infusion (DLI) is a supportive therapy currently pursued to increase GVL after bone marrow transplantation. 6, 7 Its clinical application to CB transplantation is limited by the reduced volume of CB available as a graft from a single delivery. This problem, however, could be solved by using as DLI ex vivo expanded T (CD3 + ) cells obtained from a portion of the CB unit 8 and pre-clinical studies are under way to analyze the GVL effect of ex vivo-amplified neonatal T cells in leukemic and cancer patients. 8 Most of the ex vivo manipulation and amplification of T cells realized up to now [9] [10] [11] are sustained by a combination of IL-2 with either anti-CD3 or anti-CD28, 8, 9, 11 and the culture conditions include serum, either fetal bovine or human. 9, 12 Furthermore, none of these studies has investigated whether the increases in T-cell number are associated with increases in T-cell clonality.
In addition to anti-CD3 and CD28 antibodies, several growth factors, such as interleukin (IL)-2, IL-4 and IL-7, are known to regulate the lifespan and/or the activation of T lymphocytes in vitro and in vivo. [13] [14] [15] [16] The use of these growth factors for ex vivo amplification of neonatal T cells under serum-deprived conditions has not been explored as yet. This study analyses the effects of SCF, in combination with the T-cell-specific growth factors mentioned above, on ex vivo expansion of T cells, both in terms of total cell number and of total number of T-cell clones, in serumdeprived cultures of light-density CB cells. Two growth factor combinations (SCF+IL-7 and SCF+IL-7+IL-2) were found to induce levels of T-cell amplification similar to those previously reported to be sustained by anti-CD3 plus IL-2.
8,9 SCF+IL-7 were found to stimulate preferential amplification of CD4 + T cells, while SCF+IL-7+ IL-2 increased preferentially the number of CD8 + T cells. Interestingly, expansion of myeloid progenitor cells, the injection of which could result in reduced neutropenia after CB transplants, 17 was also observed in these cultures. Therefore, ex vivo culture of a fraction of a CB graft with combinations of T-cell-specific growth factors could at the same time amplify T cells, for supportive immunotherapy while maintaining the number of progenitor cells to accelerate the speed of the engraftment.
Material and methods

CB samples and cell purification
Umbilical CB was obtained at the time of delivery from uncomplicated pregnancies with previous written informed consent from the mother. Light-density mononuclear cells (LDC) were isolated from fresh specimens by density-cut separation (ro1.077) (Ficoll-Paque; Amersham-Pharmacia Biotech, Uppsala, Sweden) and either processed directly or cryopreserved in Hanks' balanced salt solution supplemented with 10% (v/v) DMSO and 50% (v/v) deionized bovine serum albumin (Sigma, St. Louis, MO, USA) for later use as described. 18 Cell culture CB-LDC (10 5 /ml) were expanded for up to 10-12 days in liquid cultures stimulated with SCF, IL-2 and IL-4 (10, 100 and 100 ng/ml, respectively, gifts from Amgen, Thousand Oaks, CA, USA), IL-3 (10 U/ml, a gift from Genetic Institute, Boston, MA, USA) and IL-7 (10 ng/ml, R&D Systems, Minneapolis, MN, USA) under serum-deprived conditions as described. 19 The cultures were demipopulated, and fresh culture medium and growth factors were added as required to keep cell concentration below 6 Â 10 5 cells/ml. The number of myeloid progenitor cells (CFC) was evaluated in cultures made semisolid with methylcellulose (0.8% w/v) dissolved in Iscove's modified Dulbecco's medium (IMDM) and stimulated with a mixture of growth factors including IL-3 (10 U/ml), SCF (10 ng/ml), erythropoietin (Epo, 1.5 U/ml, Epoetina a, Dompe`Biotec, Milan, Italy), granulocyte colony-stimulating factor (G-CSF, 10 ng/ml, Filgrastim, Dompe`Biotec) and granulocyte-macrophage colony-stimulating factor (GM-CSF, 10 ng/ml, Molgramostim, Sandoz, Milan, Italy) as previously described. 20 The colonies derived from burstforming units, erythroid (BFU-E), colony-forming units, granulo-monocytic (CFU-GM) and mixed, erythroid and myeloid (CFU-mix) progenitor cells were scored according to standard criteria after 14 days of incubation in a fully humidified CO 2 /O 2 (5% each) monitored incubator.
Immunophenotyping by flow cytometry
Cells were washed twice in phosphate-buffered saline and incubated (1-5 Â 10 5 cells per tube) at 41C for 30 min with antibodies against CD3, CD4, CD7, CD8, CD45 (all from Sigma), CD45RA, CD45RO (both from Beckman Coulter Inc, Fullerton, CA, USA), CD19, CD34 (both from Becton Dickinson, Franklin Lakes, NJ, USA), CD2 and CD33 (PharMingen, San Diego, CA, USA), all labeled with appropriate fluorochromes. Aliquots of the cells were also incubated with appropriate isotype-matched antibodies as controls for non specific binding. Two-and three-color cytofluorimetric analysis and cell sorting of CD4 and CD8 single positive cells were performed with a Coulter Elite ESP Cell Sorter (Coulter, Miami, FL, USA).
Mixed lymphocyte reaction (MRL)
Mixed lymphocyte cultures were obtained by incubating LDC from either adult peripheral blood (PB) or from CB, or lymphocytes obtained after culturing CB-LDC for 10 days in the presence of SCF and IL-7 (10 5 cells per well per three replicate wells) in the presence of irradiated autologous LDC (either from PB or CB, as appropriate) or irradiated allogeneic PB-LDC (2 Â 10 5 cells per well in all cases). 21 The cells used as stimulators had been irradiated at 1000 rad with the GAMMA CELL 220 (Atomic Energy Canada Ltd, Toronto, Canada). Each well contained 0. ) were lysed with guanidine isothiocyanate (RNAFAST, Molecular System, San Diego, CA, USA) and cDNA was prepared by reverse transcription with Moloney RT and random primers (Gibco-BRL, Grand Island, NY, USA). Individual nongermline configurations of the TCR V b chains were amplified by RT-PCR using a common primer coupled with a primer specific for each of the 22 V b family variable elements as described. 22 cDNA obtained from RNA extracted from an equivalent number of cells was amplified with Pfu DNA polymerase (0.5 U/ reaction, Stratagene USA, La Jolla, CA, USA) for 35 cycles in a PTC-100 Thermocycler (MJ Research Inc., Watertown, MA, USA). Hypoxanthine phosphoribosyl transferase (HPRT) was amplified as control for the quality and the amount of cDNA (not shown). The amplified products were separated by electrophoresis on a 5% polyacrylamide and 10% glycerol nondenaturing gel, which was blotted onto Hybond N + membrane (Amersham-Pharmacia Biotech). The specificity of the amplification was proven by probing with an end-labeled (T4 polynucleotide kinase end-labeling kit, Gibco BRL, and g-32 P-ATP, specific activity ¼ 3000 Ci/ mmol, Du Pont, Florence, Italy) oligonucleotide specific for the constant portion of the V b elements. 23 After hybridization, the filters were washed twice under stringent conditions and exposed to X-ray films (Eastman Kodak Company, Rochester, NY, USA). All the procedures were according to standard protocols. 24 
Statistical analysis
Statistical analysis was performed with the Mann-Whitney rank sum test using SigmaStat 2.0 software for Windows (Jandel Corp., San Rafael, CA, USA).
Results
Ex vivo amplification of total nucleated cells and myeloid progenitor cells (CFC) in serum-deprived cultures of CB-LDC stimulated with lymphoid cytokine combinations
The fold increase (FI) in total nucleated cells and CFC observed after 10-11 days of serum-deprived cultures of CB-LDC (10 5 cells/ml) stimulated with lymphoid-specific growth factor combinations is presented in Figure 1 . Since no differences were observed in the ratio among individual CFC types before and after culture in any of the conditions investigated, only the total CFC number is reported for clarity. The results are compared with those obtained in cultures stimulated with SCF and IL-3, a combination known to stimulate expansion of progenitor cells from neonatal CD34 + cells. [25] [26] [27] Very few, if any, CB-LDC survived 10-12 days of serumdeprived cultures in the absence of growth factors 19, 25 or when stimulated with only one of the cytokines investigated (results not shown). SCF and IL-3 induced an increase in the number of total nucleated cells and of CFC in these cultures (average FI ¼ 3.672.13 and 5.5272.04, Po0.01, respectively) ( Figure 1 ). The presence of SCF+IL-7 increased both the total cell number (FI ¼ 6.471.17) and the CFC number (FI ¼ 8.6771.5), detected at days 10-12. The increases induced by this growth factor combination were significantly higher (Po0.01) than those observed in the presence of SCF and IL-3. On the other hand, the presence of SCF and IL-4 induced only a modest, although significant (Po0.03), increase (FI ¼ 1.970.24) in the total number of nucleated cells observed in the culture and a significant increase (FI ¼ 10.1972.0) in CFC numbers, increase that was similar to that sustained by SCF+IL-7. IL-2 had no effect, either alone or in combination with SCF (not shown), on the amplification of CB-LDC under these culture conditions. However, its further addition to culture stimulated with SCF+IL-4 abrogated the increase in CFC number sustained by this growth factor combination (average FI ¼ 1.5670.4) (Figure 1 ).
Lineage analysis of mononuclear cells expanded in serum-deprived cultures of CB-LDC
The immunophenotype of CB-LDC before and after 10-12 days of culture in the presence of the different growth combinations (SCF+IL-3, SCF+IL-7, SCF+IL-4, SCF+IL-7+IL-2 or SCF+IL-4+IL-2) is presented in Figure 2 .
Before culture, B70% of the CB-LDC expressed a low forward and side scatter characteristic of lymphoid and progenitor cells ( Table 1 ). Although as a percentage, the cells in the lymphoid gate did not increase in any of the culture conditions investigated (68-74% at day 0 vs 44-64% at day 10-12, Table 1 ), those growth factor combinations that increased the total cell numbers increased the absolute number of lymphoid cells as well.
The cells present in the lymphocyte gate were identified by FACS immunophenotyping after being stained with the CD7, CD2, CD4, CD8, CD19, CD34 and CD45 antibodies ( Figure 2 , Table 2 and results not shown). In preliminary experiments, it was verified that all of the cells in the lymphocyte gate expressed CD45 (data not shown) and, therefore, the cells in this gate were not significantly contaminated by erythroid cells. In determining the percentage of cells expressing CD4, particular care was paid in setting the gate to exclude possible contamination from CD4 + monocytes. The frequency of cells with the phenotype of T-cell precursors (CD7 + CD2 À ) remained constant when the cultures were stimulated with SCF+IL-7 (FI ¼ 2.247 0.83, Figure 2b ).
In contrast to what has been reported for most of the thymus organ culture systems developed up to now, 28-30 the Tables 1 and 2 
CD2
+ phenotype that may, at least partially, represent natural killer (NK) cells, 31 increased in frequency in almost all of the lymphoid growth factor combinations utilized (from 0.7% at day 0 to 5.5% with SCF+IL-7 and 51.0% with SCF+IL-7+IL-2, Figure 2b Table 2) .
As already reported, 21 the cells in the lymphoid gate of CB-LDC differed from those present in the LDC from adult blood (PB-LDC) in CD45RA/RO expression ( Figure 3) . While PB-LDC contained both CD45RA + and CD45RO + T cells (in a 2:1 ratio), CB-LDC expressed either CD45RA or both CD45RA and CD45RO, and very few of them (o2%) expressed only CD45RO. After 10 days of culture, the majority (490%) of CB T cells obtained in the presence of SCF+IL-7 expressed CD45RA, while those obtained in the presence of SCF+IL-7+IL-2 expressed, as PB-LDC, both CD45RA (60%) and CD45RO (30%).
RT-PCR and SSCP analysis of the TCR b-chain
To clarify whether the increases in T-cell numbers observed after 10-12 days in liquid culture of CB-LDC stimulated with SCF+IL-7 were reflected by increases in T-cell clonality, the TCR V b -chain repertoire expressed by the cell population before and after culture was compared by RT-PCR and SSCP analysis. In fact, since each T-lymphocyte clone expresses a specific TCR gene rearrangement, the complexity of V b -chain fragments ampli- All of the 22 variable TCR b-chain genes analyzed were found to be expressed by CB-LDC after 10-12 days of culture with SCF+IL-7 ( Figure 4 ). This was true even for those TCR V b genes that were not expressed or expressed The results are presented as mean (7s.e.m.) of 4-8 independent experiments, as specified by the number in parentheses. One representative experiment is presented in Figure 2 . Percentages statistically different (Po0.05) from the values observed at day 0 are indicated by an asterisk.
Table 2
Fold increase a in the total number of CD-LDC present in the low side and forward lymphocyte gate and in the number of cells expressing specific antigenic profiles observed after 10-12 days of serum-deprived culture stimulated with the indicated growth factor combinations a Fold increases were calculated on the basis of the total number of cells presented in Figure 1 and the cell percentages presented in Table 1 and Figure 2 . n=number of independent experiments analyzed . b.d.=below detectable levels. Significance levels (*Po0.05; **Po0.01; ***Po0.005) were calculated by Mann-Whitney rank sum test. The proliferation in MLR of T cells obtained from CB-LDC cultured for 10 days in the presence of SCF+IL-7 is presented in Table 3 . The data are compared with those obtained with LDC prepared from CB or adult PB. As already described, 21 PB-LDC proliferated very little in the presence of medium alone or of autologous irradiated LDC as stimulators. These cells incorporated high levels of [ On the other hand, CB-LDC expressed basal (medium or autologous LDC) proliferation rates significantly higher than those expressed by PB-LDC. They expressed also a high sample to sample variability in their capacity to proliferate in response to irradiated allogeneic PB-LDC. For this reason, on average, their proliferation rate in the presence of PB-LDC was not significantly different from that observed under basal conditions. No difference was observed between the proliferation in MLR of CB-LDC before or after culture, with the exception of a significant reduction in proliferation when the cells were stimulated with irradiated autologous LDC.
Liquid culture of purified CD4
+ and CD8 + T cells stimulated with SCF+IL-7 or SCF+IL-7+IL-2.
To assess the capacity of mature T cells to proliferate under the culture conditions described here, CD4 + or CD8 + cells were purified by cell sorting from CB-LDC, mixed in a 1:1 ratio and cultured at an initial concentration of 10 5 per ml in the presence of either SCF+IL-7 or SCF+IL-7+IL-2 ( Figure 6 ). The total numbers of cells present in the lymphocyte gate remained constant for up to 20 days of culture. All of the cultured cells, present in the lymphocyte gate, were viable (by propidium iodide exclusion, results not shown) and expressed CD3 + (T cells) (Figure 6b ). Since a significant proportion of the events were found in the side and forward scatter area characteristic of cellular debris (Figure 6b ), the number of T cells was likely maintained constant by the balance between proliferation and death. The levels of CD4 and CD8 expression on the cell surface decreased after culture but the CD4 + /CD8 + cell ratio remained similar to the input value (B 1:1) both in cultures stimulated with SCF+IL-7 or SCF+IL-7+IL-2, indicating that no preferential survival/proliferation of CD4 + over CD8 + cells occurred in any of the two culture conditions.
The TCR V b -chain rearrangement expressed by the purified T cells before and after 10 days of culture is presented in Figure 6c . This particular specimen expressed at day 0 all of the different V b genes analyzed. Some genes were expressed with a polyclonal pattern (V b 1, 2, 6.1, etc.), while others were expressed with an oligoclonal (5.1, 13.2, 15, 16, etc.) or even a monoclonal rearrangement pattern (4 and 12) Figure 6c ). Such variability could be due either to random selection of individual T-cell clones or to selective survival of a specific T-cell population. Experiments are under way to clarify this point.
Discussion
We have characterized the T-cell expansion obtained in serum-deprived cultures of neonatal hemopoietic cells. To reproduce conditions that most likely will be used in clinical settings, the cultures were seeded with the mononuclear fraction of CB, although in selected experiments purified neonatal T cells were cultured under the same conditions for comparison. The cultures were stimulated with the early multilineage cytokine SCF in combination with either IL-3, a factor known to stimulate proliferation of CD34 + cells Ex Vivo T-cell amplification M Sanchez et al purified from either neonatal [25] [26] [27] or adult 33 specimens, or with IL-7, IL-4 and IL-2, cytokines known for their activity on lymphoid cells. 34 IL-7 provides nonredundant signals for T-and B-cell development and is produced by the same stromal cells that produce SCF in the fetal liver, in the adult bone marrow and in the thymus, 14, 35 where the highest + and CD8 + T cells purified by cell sorting from CB-LDC and cultured for 10 days in the presence of either SCF and IL-7 or SCF, IL-7 and IL-2. The gating used for the purification and the reanalysis for CD4 and CD8 expression by the purified cells are indicated in (a). The immunophenotyping for CD3 and CD4/CD8, and the V b gene fragments expressed by the cells after culture are shown in (b) and (c), respectively. The Vb gene rearrangements were analyzed in parallel before and after culture for direct comparison. Therefore, the results at day 0 represent two independent analyses of the same sample population. levels of IL-7 production occur in vivo.
36 On the other hand, although mouse models have demonstrated that IL-2 and IL-4 are dispensable for appropriate lymphoid development in vivo, 15, 16 these growth factors that are produced mainly by specific T-cell subsets upon activation, 37, 38 play important roles in regulating T-cell function in vitro.
In contrast with what has been reported for purified CD34 + cells, [25] [26] [27] 33 SCF+IL-3 did not increase the number of total nucleated cells observed after 10-12 days in serum-deprived culture of CB-LDC and induced only a modest (5-fold) increase in the total number of CFC (Figure 1 ). Such modest increases are likely to be because of the fact that, in contrast with the purified cells, LDC contains a high proportion of differentiated cells that die out during the culture masking the output of newly differentiated cells from the progenitor cell compartment. As expected, most of the cells grown in the presence of this growth factor combination fall outside the lymphocyte gate (Figure 2a ), and were identified as myeloid (CD33 + ) cells (data not shown). These results unveil a lineage species specificity for the action of these two growth factors: in fact, SCF and IL-3 have been reported to induce T-cell differentiation in cultures of murine marrow cells 29, 39 but are a poor stimulus for T-cell proliferation in cultures of human cells where they sustain preferential amplification of myeloid cells ( [25] [26] [27] 33 and this manuscript).
In agreement with the biological activity briefly summarized above, IL-7 was the only cytokine found to synergize with SCF in sustaining amplification of T cells. In fact, the combination of SCF+IL-7 increased the total number of cells observed after 10 days of culture more than any other growth factor combination analyzed ( Figure 1 and Table 1 ). Such an increase in total cell number was associated with increases in cells of the lymphoid compartment ( Figure 2 and Table 2 ). Both CD4 + and CD8 + cells increased after SCF+IL-7 stimulation, although CD4 + cells were preferentially amplified (Table 2 and Figure 2) . Analysis of the TCR b-chain gene rearrangements showed that the increases in T-cell number were associated with increases in T-cell clonality (Figures 4 and 5) . Therefore, the T-cell amplification observed in these cultures was not only because of amplification of clones already significantly represented in the original CB-LDC population but new clones that were not present at day 0, also became manifest with time in culture. The dynamic pattern of expression of the TCR b-chain rearrangements observed in the timecourse analysis indicates that different individual Tlymphocyte clones become prevalent at any given time in culture ( Figure 5 ). It is possible that new T-cell clones are continuously generated de-novo in cultures of CB-LDC from precursor/progenitor cells and that those clones disappear after an initial amplification because they lack a still to be identified survival stimulus. Support for this interpretation is provided by reports that stem/progenitor cells differentiate into mature CD4 + or CD8 + T cells in culture not only in the presence of accessory cells of thymic origin, 28, 30, 40 but also in the presence of certain cell lines 41 and of accessory cells present in the murine marrow 42 and in human neonatal blood. 19 However, the hypothesis that in the cultures described here, T-cells are derived by differentiation of an early compartment is in contrast with the observation that the frequencies of the T-cell precursors (CD7 + /CD2
À and CD4 + /CD8 + ) were found to be only modestly increased. Alternatively, the dynamic pattern of rearrangements observed in these cultures could simply reflect stochastic variations in the proliferation of individual T-cell clones. To directly exclude this possibility, purified neonatal CD4 + and CD8 + T cells were cultured under the same conditions that had been found to sustain the best proliferation of T cells from CB-LDC. Purified T cells proliferated less efficiently and expressed a lower number of TCR V b gene rearrangements than CB-LDC. Furthermore, while in culture of CB-LDC stimulated with SCF+IL-7, CD4
+ cells increased preferentially over CD8 + cells (Table 2 ), the two cell populations had similar survival when cultured as purified cells (Figure 6b ).
IL-2 had no biological activity when used directly in combination with SCF, but exerted very distinct effects when either IL-4 or IL-7 was also present in the culture system. Its addition to the combination of SCF+IL-7 suppressed amplification of CD4 + T cells, favored the amplification of CD8 + T cells and did not affect the number of CFC generated over time. On the other hand, when used in combination with SCF+IL-4, it had no effect on the T-cell compartments, but completely abrogated the amplification of progenitor cells induced by this growth factor combination. Therefore, the cellular levels of its action (progenitor cells vs differentiated T cells) and the type (inhibitory or stimulatory) were linked to whether IL-4 or IL-7 were also present. The receptor complexes for IL-2, IL-4 and IL-7 display a similar organization characterized by the association of the cytokine-specific binding subunit with a signaling b subunit common to all of the three growth factors. [43] [44] [45] [46] The results presented here indicate that the binding subunits may establish specific competitions for the signaling common subunit in different T-cell populations (ie, progenitor cells and differentiated T cells). It is possible that at the progenitor levels, the IL-2-binding subunit competes with the IL-4-binding subunit for activation of the common subunit while at the T-cell levels, the IL-2-and IL-7-binding subunits synergize in activating the common subunit.
In conclusion, we report that either SCF+IL-7 or SCF+IL-7+IL-2 sustain in vitro amplification of T cells at levels comparable to those reported to be induced by the combination of IL-2 and anti-CD3 antibody. 8, 9, 11 The increases in T-cell number were associated with a considerable increase in the complexity of the TCR repertoire expressed by the cultured T cells. Although the levels of amplification achieved in this paper were lower than those induced by the mitogens concanavalin A and mezerein, 10 it is debatable whether mitogens will be used for clinical purposes in the near future. Furthermore, in contrast to all the conditions for T-cell amplification established up to now, stimulation of CB-LDC with lymphoid-specific growth factor combinations sustained not only amplification of T cells but also that of progenitor cells. Therefore, amplification of T cells for supportive immunotherapy can occur under the same culture conditions that maintain progenitor cells for myeloid engraftment.
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